TY - JOUR
T1 - In-Hospital Hyperglycemia Is Associated With Worse Outcomes in Patients Admitted With COVID-19
AU - Lombardi, Angela
AU - Agarwal, Shivani
AU - Schechter, Clyde
AU - Tomer, Yaron
N1 - Funding Information:
Funding. This research was supported in part by the Center for Scientific Review, National Institutes of Health (grants UL1TR002556, KL2TR002558, and part of 2P30DK020541-45 to A.L. and DK067555 to Y.T.), as well as by the Diabetes Action and Education Foundation (to A.L.).
Publisher Copyright:
© 2022 by the American Diabetes Association.
PY - 2022/11
Y1 - 2022/11
N2 - OBJECTIVE Diabetes and the outpatient diabetes treatment regimen have been identified as risk factors for poor outcomes in patients with sepsis. However, little is known about the effect of tight inpatient glycemic control in the setting of coronavirus disease 2019 (COVID-19). Therefore, we examined the effect of hyperglycemia in patients with diabetes hospitalized because of COVID-19. RESEARCH DESIGN AND METHODS We analyzed data from 1,938 COVID-19 patients with diabetes hospitalized for COVID-19 from March to May 2020 at a large academic medical center in New York City. Patients were divided into two groups based on their inpatient glycemic values, and a Cox proportional hazards regression model was used to assess the independent association of inpatient glucose levels with mortality (primary outcome) and the risk of requiring mechanical ventilation (MV) (secondary outcome). RESULTS In our analysis, 32% of the patients were normoglycemic and 68% hyperglycemic. Moreover, 31% of the study subjects died during hospitalization, and 14% required MV, with inpatient hyperglycemia being significantly associated with both mortality and the requirement for MV. Additionally, in the Cox regression analy-sis, after adjustment for potential confounders, including age, sex, race, BMI, HbA1c, comorbidities, inflammatory markers, and corticosteroid therapy, patients with uncontrolled hyperglycemia had a higher risk of dying (hazard ratio [HR] 1.54, 95% CI 1.00–2.36, P = 0.049) and of requiring MV (HR 4.41, 95% CI 1.52–2.81, P = 0.006) than those with normoglycemia. CONCLUSIONS A tight control of inpatient hyperglycemia may be an effective method for im-proving outcomes in patients with diabetes hospitalized for COVID-19.
AB - OBJECTIVE Diabetes and the outpatient diabetes treatment regimen have been identified as risk factors for poor outcomes in patients with sepsis. However, little is known about the effect of tight inpatient glycemic control in the setting of coronavirus disease 2019 (COVID-19). Therefore, we examined the effect of hyperglycemia in patients with diabetes hospitalized because of COVID-19. RESEARCH DESIGN AND METHODS We analyzed data from 1,938 COVID-19 patients with diabetes hospitalized for COVID-19 from March to May 2020 at a large academic medical center in New York City. Patients were divided into two groups based on their inpatient glycemic values, and a Cox proportional hazards regression model was used to assess the independent association of inpatient glucose levels with mortality (primary outcome) and the risk of requiring mechanical ventilation (MV) (secondary outcome). RESULTS In our analysis, 32% of the patients were normoglycemic and 68% hyperglycemic. Moreover, 31% of the study subjects died during hospitalization, and 14% required MV, with inpatient hyperglycemia being significantly associated with both mortality and the requirement for MV. Additionally, in the Cox regression analy-sis, after adjustment for potential confounders, including age, sex, race, BMI, HbA1c, comorbidities, inflammatory markers, and corticosteroid therapy, patients with uncontrolled hyperglycemia had a higher risk of dying (hazard ratio [HR] 1.54, 95% CI 1.00–2.36, P = 0.049) and of requiring MV (HR 4.41, 95% CI 1.52–2.81, P = 0.006) than those with normoglycemia. CONCLUSIONS A tight control of inpatient hyperglycemia may be an effective method for im-proving outcomes in patients with diabetes hospitalized for COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85141351761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141351761&partnerID=8YFLogxK
U2 - 10.2337/dc22-0708
DO - 10.2337/dc22-0708
M3 - Article
C2 - 36041197
AN - SCOPUS:85141351761
SN - 0149-5992
VL - 45
SP - 2683
EP - 2688
JO - Diabetes care
JF - Diabetes care
IS - 11
ER -